The best of hypertension 2005;L'essentiel de 2005 en hypertension artérielle

Archives des Maladies du Coeur et des Vaisseaux

Volumn 99, Issue SPEC. ISS. 1, 2006, Pages 35-41

  Chamontin, B ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PERINDOPRIL; THIAZIDE DIURETIC AGENT; TUMOR NECROSIS FACTOR ALPHA; ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PROGNOSIS; STROKE; CEREBROVASCULAR ACCIDENT; INFLAMMATION; PATHOPHYSIOLOGY; PUBLISHING; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; CEREBROVASCULAR ACCIDENT; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; INFLAMMATION; PUBLISHING; RISK FACTORS;

EID: 33645299356     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic Value of Ambulatory and Home Blood Pressures Compared with Office Blood Pressure in the General Population. Follow-Up Results From the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) Study. Circulation 2005;111:1777-83.
2. Bombelli M, Sega R, Facchetti R, Corrao G, Friz HP, Vertemati AM, et al. Prevalence and clinical significance of a greater ambulatory versus office blood pressure ("reversed white coat" condition) in a general population. J Hypertens 2005;23:513-20.
3. Mancia G, Facchetti R, Bombelli M, Friz HP, Grassi G, Giannattasio C, et al. Relationship of Office, Home, and Ambulatory Blood Pressure to Blood Glucose and Lipid Variables in the PAMELA Population. Hypertension 2005;45:1072-7.
4. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, et al. Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol 2005;46:508-15.
5. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension 2005;45:240-5.
6. Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, et al. Prognostic significance of night-time, early morning and daytime blood pressures on the risks of cerebro and cardiovascular mortality. J Hypertens 2005;23:S16 (abstract).
7. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTT-BPLA): a mulicentre randomised controlled trial. Lancet 2005;366:895-906.
8. Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfied M, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowerinf Arm (ASCOT-BPLA). Lancet 2005;366:907-13.
9. Staessen JA, Birkenhager WH. Evidence that new antihypertensives are superior to older drugs. Lancet 2005;366:869-71.
10. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivolio M Thijs L, et al. Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention. Hypertension 2005;46:386-92.
11. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305-15.
12. Thuillez C, Richard V. Targeting endothelial dysfunction in hypertensive subjects. J Hum Hypertens 2005;19:21-5.
13. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIME 22) investigators. N Engl J Med 2005;352:20-8.
14. Abramson JL, Weintraub WS, Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 2002;39:197-202.
15. Amar J, Ruidavets JB, Peyrieux JC, Mallion JM, Ferrières J, Safar ME, et al. C-reactive protein elevation predicts pulse pressure reduction in hypertensive subjects. Hypertension 2005;46:151-5.
16. Kullo IJ, Seward JB, Bailey KR, Bielak LF, Grossardt BR, Sheedy PF, et al. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. Am J Hypertens 2005;18:1123-9.
17. Tsioufis C, Stougiannos P, Kakkavas A, Toutouza M, Mariolis A, Vlasseros I, et al. Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension. Am J Cardiol 2005;96:252-6.
18. Cifkova R, Frohlich J, Skodova Z, Lanska V, Adamkova V, Bojanovska E, et al. C-reactive protein and the risk of developing the metabolic syndrome. A population study (abstract). J Hypertens 2005;23:S109.
19. Recommandations HAS-2005 sur la prise en charge des patients adultes atteints d'HTA essentielle. Site web : http://www.has.sante.fr
20. Radi S, Lang T, Lauwers-Cances V, Chatellier G, Fauvel JP, Larabi L, et al. One-year hypertension incidence and its predictors in a working population: the IHPAF study. J Hum Hypertens 2004;18:487-94.
21. Inamo J, Lang T, Atallah A, Inamo A, Larabi L, Chatellier G, et al. Prevalence and therapeutic control of hypertension in French Caribbean reqions. J Hypertens 2005;23:1341-6.
22. Laude D, Elghozi JL, Girard A, Bellard E, Bouhaddi M, Castiglioni P, et al. Comparison of various techniques used to estimate spontaneous baroreflex sensitivity (the EuroBaVar study). Am J Physiol Regul Integr Comp Physiol 2004;286:226-31.